FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3064272893> ?p ?o ?g. }

• W3064272893 endingPage "175883592092863" @default.
• W3064272893 startingPage "175883592092863" @default.
• W3064272893 abstract "Targeted therapies offer novel opportunities to explore biomarkers based on their mode of action. Taking this into consideration, we evaluated six angiogenesis-related proteins as potential predictive biomarkers, which expression might predict the benefit of bevacizumab treatment in patients with metastatic colorectal cancer (mCRC).This was a phase II multicenter, two-armed, randomized study, in which patients with mCRC were treated with XELIRI (capecitabine and irinotecan) plus bevacizumab followed by XELOX (capecitabine and oxaliplatin) plus bevacizumab (Arm A) or the reverse sequence (Arm B). Tissue expression level of six prespecified candidates [microvessel density assessed by CD31, PTEN, αV integrin, CD98hc, uPAR and NRP-1] was analyzed via immunohistochemistry. The prognostic impact on survival was quantified using the Cox regression model. The predictive potential for benefit from Arm A versus Arm B treatment was investigated by fitting an interaction between the biomarkers and treatment assignment within a multivariable Cox model.In total, 74 out of 126 patients were included in the analysis. The expression of PTEN, αV integrin, uPAR and NRP-1 was not associated with progression-free survival (PFS) or overall survival (OS). For the first time, we identified that patients with tumors expressing CD98hc had a longer PFS than patients without CD98hc-expression (p = 0.032). More importantly, and in accordance with previous studies, low microvessel density was found to be associated with a reduced PFS [adjusted HR per doubling of CD31-expression (p = 0.53, 95% confidence interval: 0.30-0.95, p = 0.034)].These results can contribute to the development of a personalized strategy for the treatment of mCRC with bevacizumab." @default.
• W3064272893 created "2020-08-24" @default.
• W3064272893 creator A5001392319 @default.
• W3064272893 creator A5002216760 @default.
• W3064272893 creator A5002926775 @default.
• W3064272893 creator A5005593510 @default.
• W3064272893 creator A5017933929 @default.
• W3064272893 creator A5034847353 @default.
• W3064272893 creator A5043085369 @default.
• W3064272893 creator A5047374036 @default.
• W3064272893 creator A5050482686 @default.
• W3064272893 creator A5050723515 @default.
• W3064272893 creator A5056149600 @default.
• W3064272893 creator A5060456745 @default.
• W3064272893 date "2020-01-01" @default.
• W3064272893 modified "2023-09-25" @default.
• W3064272893 title "Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC" @default.
• W3064272893 cites W1527111349 @default.
• W3064272893 cites W1967997906 @default.
• W3064272893 cites W1973216217 @default.
• W3064272893 cites W2001367419 @default.
• W3064272893 cites W2002019030 @default.
• W3064272893 cites W2002753332 @default.
• W3064272893 cites W2005348280 @default.
• W3064272893 cites W2010300658 @default.
• W3064272893 cites W2017297828 @default.
• W3064272893 cites W2033445130 @default.
• W3064272893 cites W2057241633 @default.
• W3064272893 cites W2067817921 @default.
• W3064272893 cites W2098617640 @default.
• W3064272893 cites W2103532601 @default.
• W3064272893 cites W2109491042 @default.
• W3064272893 cites W2109561752 @default.
• W3064272893 cites W2127905380 @default.
• W3064272893 cites W2130948044 @default.
• W3064272893 cites W2139505515 @default.
• W3064272893 cites W2157019123 @default.
• W3064272893 cites W2159789252 @default.
• W3064272893 cites W2334041313 @default.
• W3064272893 cites W2470575266 @default.
• W3064272893 cites W2562308108 @default.
• W3064272893 cites W2590857018 @default.
• W3064272893 cites W2597860819 @default.
• W3064272893 cites W2601868035 @default.
• W3064272893 cites W2620065392 @default.
• W3064272893 cites W2742486699 @default.
• W3064272893 cites W2746050808 @default.
• W3064272893 cites W2767216199 @default.
• W3064272893 cites W2794416238 @default.
• W3064272893 cites W2889620869 @default.
• W3064272893 cites W2889646458 @default.
• W3064272893 cites W2892367714 @default.
• W3064272893 cites W2941832417 @default.
• W3064272893 cites W2943004339 @default.
• W3064272893 cites W2946023556 @default.
• W3064272893 doi "https://doi.org/10.1177/1758835920928635" @default.
• W3064272893 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7446555" @default.
• W3064272893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32922518" @default.
• W3064272893 hasPublicationYear "2020" @default.
• W3064272893 type Work @default.
• W3064272893 sameAs 3064272893 @default.
• W3064272893 citedByCount "12" @default.
• W3064272893 countsByYear W30642728932021 @default.
• W3064272893 countsByYear W30642728932022 @default.
• W3064272893 countsByYear W30642728932023 @default.
• W3064272893 crossrefType "journal-article" @default.
• W3064272893 hasAuthorship W3064272893A5001392319 @default.
• W3064272893 hasAuthorship W3064272893A5002216760 @default.
• W3064272893 hasAuthorship W3064272893A5002926775 @default.
• W3064272893 hasAuthorship W3064272893A5005593510 @default.
• W3064272893 hasAuthorship W3064272893A5017933929 @default.
• W3064272893 hasAuthorship W3064272893A5034847353 @default.
• W3064272893 hasAuthorship W3064272893A5043085369 @default.
• W3064272893 hasAuthorship W3064272893A5047374036 @default.
• W3064272893 hasAuthorship W3064272893A5050482686 @default.
• W3064272893 hasAuthorship W3064272893A5050723515 @default.
• W3064272893 hasAuthorship W3064272893A5056149600 @default.
• W3064272893 hasAuthorship W3064272893A5060456745 @default.
• W3064272893 hasBestOaLocation W30642728931 @default.
• W3064272893 hasConcept C121608353 @default.
• W3064272893 hasConcept C126322002 @default.
• W3064272893 hasConcept C143998085 @default.
• W3064272893 hasConcept C185592680 @default.
• W3064272893 hasConcept C190283241 @default.
• W3064272893 hasConcept C204232928 @default.
• W3064272893 hasConcept C2776694085 @default.
• W3064272893 hasConcept C2777609662 @default.
• W3064272893 hasConcept C2777802072 @default.
• W3064272893 hasConcept C2777909004 @default.
• W3064272893 hasConcept C2778939058 @default.
• W3064272893 hasConcept C2780259306 @default.
• W3064272893 hasConcept C2780394083 @default.
• W3064272893 hasConcept C2780521871 @default.
• W3064272893 hasConcept C2780962732 @default.
• W3064272893 hasConcept C526805850 @default.
• W3064272893 hasConcept C55493867 @default.
• W3064272893 hasConcept C71924100 @default.
• W3064272893 hasConcept C86554907 @default.

• next